Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 14, 2026Annals of HematologyOpen Access

Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registry

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJonas WelschFSFelicitas SchulzAKAnnika Kasprzak

Discussion

Loading...

Member takes

Overview

Analysis shows improved survival rates in myelodysplastic neoplasms from varied therapies, suggesting better outcomes over time.

Key Points

  • The aim is to evaluate the impact of different therapy strategies on overall survival in patients with myelodysplastic neoplasms across decades.
  • Data analysis from the German MDS registry involving 1,147 patients
  • Comparison of median survival rates across three diagnostic periods
  • Examination of treatment modalities including allogeneic SCT and best supportive care
  • Median survival improved from 20 months (until 2000) to 57 months (after 2011)
  • Allogeneic SCT patients exhibited the best median survival of 108 months
  • Increase in allogeneic SCT recipients from 6.3% to 40% across the study periods
  • Improved OS noted among patients receiving best supportive care alone with a rise from 17 to 64 months

Cite This Study

Welsch et al. (2026) studied this question.

synapsesocial.com/papers/69ddd9f9e195c95cdefd7635https://doi.org/10.1007/s00277-026-06736-4
View Full Paper
Ask AI
Bookmark
Share